Monoclonal antibodies, which have been approved for immunological, anti-infective, ophthalmic, cancer and other categories, represent one of the most successful therapeutic drug classes.  Ten monoclonal antibodies have been approved for cancer therapy alone, including three blockbuster products sold by the Roche Group (RHHBY) – Avastin® , Rituxan® , and Herceptin® that collectively represented...
Read More »

In September 2009, Osiris Therapeutics, Inc. (OSIR) reported preliminary results from two Phase III trials evaluating its Prochymal product candidate for the treatment of acute Graft-versus-Host disease .  Unfortunately, neither trial reached its primary endpoint, sending shares from $14 to a 52-week low of $5.35 by November 2009.  The results were the latest in...
Read More »